Nakamura Hiroshi, Hara Takeshi, Mabuchi Ryoko, Matsumoto Takuro, Nakamura Nobuhiko, Ninomiya Soranobu, Kitagawa Junichi, Kanemura Nobuhiro, Kito Yusuke, Takami Tsuyoshi, Miyazaki Tatsuhiko, Takeuchi Tamotsu, Shimizu Masahito, Tsurumi Hisashi
First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
Department of Hematology, Matsunami General Hospital, Kasamatsu-cho, Hashima-gun, Gifu 501-6062, Japan.
Mol Clin Oncol. 2022 Jan;16(1):4. doi: 10.3892/mco.2021.2437. Epub 2021 Nov 4.
Oxidative stress serves an important role in carcinogenesis. The present study investigated the clinical significance of oxidative stress as a prognostic factor for diffuse large B-cell lymphoma (DLBCL). The participants comprised 55 consecutive patients with DLBCL. A commercially available derivatives of reactive oxygen metabolites (d-ROMs) test kit was used to assess oxidant levels. Similarly, a commercially available biological antioxidant potential (BAP) test was used to assess antioxidant levels. The antioxidative/oxidative stress ratio was calculated as d-ROMs/BAP. The median serum concentration of d-ROMs was 425 µM. The levels of d-ROMs were significantly higher in patients with DLBCL than in healthy volunteers (P<0.01). The complete remission (CR) rates in patients with d-ROMs <425 and ≥425 µM were 81.5 and 85.7%, respectively [not significant (NS)]. The 3-year overall survival (OS) rates for patients with d-ROMs <425 and ≥425 µM were 67.2 and 72.0%, respectively (NS). The median BAP was 2,002 µM. The CR rates of patients with BAP <2,002 and ≥2,002 µM were 77.8 and 88.9%, respectively (NS). The 3-year OS rates of patients with BAP <2,002 and ≥2,002 µM were 60.9 and 75.9%, respectively (NS). No significant difference in the d-ROMs/BAP ratio was observed between groups. Multivariate analysis revealed that d-ROMs were an independent prognostic factor for progression-free survival.
氧化应激在肿瘤发生过程中发挥着重要作用。本研究探讨了氧化应激作为弥漫性大B细胞淋巴瘤（DLBCL）预后因素的临床意义。研究对象为55例连续的DLBCL患者。使用市售的活性氧代谢物衍生物（d-ROMs）检测试剂盒评估氧化剂水平。同样，使用市售的生物抗氧化能力（BAP）检测来评估抗氧化剂水平。抗氧化/氧化应激比计算为d-ROMs/BAP。d-ROMs的血清中位浓度为425μM。DLBCL患者的d-ROMs水平显著高于健康志愿者（P<0.01）。d-ROMs<425μM和≥425μM的患者完全缓解（CR）率分别为81.5%和85.7%[无显著差异（NS）]。d-ROMs<425μM和≥425μM的患者3年总生存率（OS）分别为67.2%和72.0%（NS）。BAP的中位值为2,002μM。BAP<2,002μM和≥2,002μM的患者CR率分别为77.8%和88.9%（NS）。BAP<2,002μM和≥2,002μM的患者3年OS率分别为60.9%和75.9%（NS）。两组之间d-ROMs/BAP比值未观察到显著差异。多变量分析显示，d-ROMs是无进展生存期的独立预后因素。
